Navigation Links
CoLucid Pharmaceuticals to Present at Sofinnova Japan Biopharma Partnering Conference on Tuesday, October 4th in Tokyo, Japan
Date:9/29/2011

DURHAM, N.C., Sept. 29, 2011 /PRNewswire/ -- CoLucid Pharmaceuticals, Inc., a privately held biopharmaceutical company, announced today that its Chief Executive Officer, Thomas P. Mathers, will be making a company presentation at the Sofinnova Japan Biopharma Partnering Conference at 9:35 – 10:00 a.m. on Tuesday, October 4th, 2011 in the Nami room at the Conrad Hotel in Tokyo, Japan. The partnering meeting is expected to attract over 300 participants from around the globe including business development executives from pharmaceutical companies and investors.

The Company is speaking with potential partners and is interacting with the FDA, and plans to advance its lead program, lasmiditan, for the treatment of acute migraine with or without aura, into pivotal studies in 2012.

About Lasmiditan

Lasmiditan is a first-in-class Neurally Acting Anti-Migraine Agent (NAAMA) designed to deliver efficacy in migraine without the vasoconstrictor activity associated with previous generations of migraine therapies.  Lasmiditan is a member of a novel chemical class called "ditans" and, unlike triptans, penetrates the central nervous system (CNS) and selectively targets 5-HT1F receptors expressed in the trigeminal pathway.  Lasmiditan does not interact with vasoconstrictor 5-HT1B/1D receptors activated by triptans.

Five clinical studies have been successfully completed outside of the U.S., including a Phase 2b double blind placebo controlled oral dose ranging study treating a single migraine attack which was completed in 2010. In the Phase 2b study, lasmiditan achieved its primary endpoint of reducing a moderate or severe headache at baseline to mild or none 2 hours after dosing (p<0.0001) in 391 patients. Differentiation of individual doses from placebo was seen as early as 30 minutes after dosing. Lasmiditan also achieved secondary endpoints, including relief of nausea, photophobia and phonophobia.  Importantly, because there was no evidence of drug-related cardiovascular effects or chest symptoms in the previous five clinical studies, CoLucid expects the pivotal Phase 3 studies to confirm that lasmiditan's side effect profile is highly differentiated from triptans and ergotamines.

About CoLucid Pharmaceuticals, Inc.

CoLucid was founded in 2005 by Pappas Ventures to advance innovative drug candidates with the potential to provide safe and effective treatments for CNS disorders. The company's investors include Pappas Ventures, Domain Associates, Care Capital, Pearl Street Venture Funds and Triathlon Medical Ventures. The company's pipeline includes lasmiditan, a novel treatment for migraine headache, COL-204 for wake promotion, and a conjugated stigmine platform that has generated a series of preclinical candidates for the chronic pain, Alzheimer's disease and psychiatric disorders. For more information, please visit CoLucid at www.colucid.com.


'/>"/>
SOURCE CoLucid Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. CoLucid Pharmaceuticals Raises $7.5 Million of Planned $9.5 Million
2. CoLucid Pharmaceuticals Receives Clearance for Investigational New Drug (IND) Application for Lasmiditan for the Treatment of Acute Migraine
3. CoLucid Appoints Thomas P. Mathers as Chief Executive Officer
4. Top 450 Biotechnology (Pharmaceuticals) Report (Global)
5. McNEIL-PPC, Inc. Acquires Full Ownership of the Johnson & Johnson-Merck Consumer Pharmaceuticals Co. Joint Venture
6. Onyx Pharmaceuticals Submits New Drug Application for Carfilzomib in Relapsed and Refractory Multiple Myeloma
7. Valeant Pharmaceuticals Announces Approval Of Colesevelam Hydrochloride In Canada
8. Ampio Pharmaceuticals Receives Notice of Allowance of its Two Patent Applications on the Combination of Zertane™ with Erectile Dysfunction Drugs in Canada
9. AcelRx Pharmaceuticals Appoints Mark G. Edwards To Its Board of Directors
10. Adamas Pharmaceuticals Initiates a Phase 2/3 Clinical Study of ADS-5102 for Parkinsons Disease
11. Questcor Pharmaceuticals Announces Preliminary Operating Metrics for Third Quarter 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2017)... 18, 2017 EpiVax, Inc. ("EpiVax") ... and immune engineering, today announced a new ... (H7N9) vaccine. ... influenza and presents a challenge for traditional ... to be effective. Using state-of-the-art bioinformatics and molecular ...
(Date:9/12/2017)... YORK , Sept. 12, 2017   EcoVadis , the leading ... has published the first annual edition of its Global CSR Risk and ... companies evaluated by EcoVadis, based on Scorecard Ratings that analyzed nearly 800,000 ... ... Index ...
(Date:9/12/2017)... 12, 2017  ValGenesis Inc., the global leader ... pleased to announce the appointment of Dr. ... Board of Directors and Chairman of Advisory Board ... science companies to manage their entire validation lifecycle ... in this process. Furthermore, ValGenesis VLMS enables rigorous ...
Breaking Medicine Technology:
(Date:9/20/2017)... ... September 20, 2017 , ... In just a short time ... already been receiving positive feedback from customers trying the product for the first time, ... Brain Booster was developed by neurosurgeon Shawn Moore, MD, for everyone from athletes at ...
(Date:9/20/2017)... ... September 20, 2017 , ... The Centers for Medicare and ... that it will transition to using only Worksheet S-10 to distribute Disproportionate Share Hospital ... three live 60-minute complimentary webinars on October 17, 2017 at 2 P.M. ...
(Date:9/20/2017)... ... September 20, 2017 , ... Recognising that in today’s busy ... Greeny delivers positive results in just three weeks. Setting the groundwork for a ... Fitting seamlessly into hectic work and family schedules, participants can lose up to ...
(Date:9/20/2017)... ... , ... “Finn Mouseson”: follows the exciting story of a mouse as the ... out on a journey that will show that friends are to be gathered but ... author and illustrator, Melody Gersonde-Mickelson, who has earned a bachelor’s degree in Fine Arts ...
(Date:9/20/2017)... , ... September 20, 2017 , ... “Psalms of Humidity”: ... peace of mind and move the readers one step closer to God. “Psalms of ... realized that his mistakes that have been made within his life are the very ...
Breaking Medicine News(10 mins):